DNA bot targets cancer
Technology Research News
Researchers from the Weizmann Institute
in Israel have constructed a molecular-size computer that is programmed
to find signs of cancer cells, and when they are present, dispense DNA
molecules designed to eradicate those cells.
The researchers' computer is a proof-of-concept that works only
in a test tube, but the device is meant to eventually work in the human
body. The prototype shows that "autonomous, molecular-scale systems are
able to perform such complex tasks as disease diagnosis and treatment,"
said Yaakov Benenson, a researcher at the Weizmann Institute.
The computer is small enough that one trillion of them fit in
a drop of water. It is made from strands of DNA and operates in liquid.
It analyzes the messenger RNA molecules in its environment, and when it
finds a balance of RNA levels that indicate a type of cancer it is programmed
to recognize, it releases DNA molecules designed to cause cancer cells
DNA consists of four types of bases -- adenine, cytosine, guanine
and thymine -- connected to a sugar-phosphate backbone. The familiar double
helix of biological DNA consists of a double strand with connected base
pairs. Messenger RNA is a carbon copy of portions of the DNA stored in
the nucleus of the cell, and indicates that those portions of the DNA
The molecular computer consists of three modules: input, computation
The input module consists of single strands of DNA that contain
stretches of bases that pair up with and so identify certain stretches
of messenger RNA. The computation module processes a series of input modules
to determine whether the balance of certain types of messenger RNA indicates
the presence of cancer cells. The output module administers a drug in
the form of another DNA strand when cancer cells are indicated.
The researchers' prototype includes a second type of DNA computer
that is programmed to release a DNA strand that inhibits the first computer's
drug molecule if cancer cells are not present. Both DNA computers must
register the presence of cancer cells for the cancer-fighting DNA strand
to be administered.
The researchers' previous work and that of other researchers showed
that DNA can be made to perform computations using DNA's ability to match
up sequences of base pairs, and enzymes, which can be used to snip strands.
The researchers recently developed a DNA computer that operates
without human intervention. They modified the autonomous computer to make
the cancer-detecting computer. "We took our existing molecular computer
and [changed] its program [to respond] to abnormal messenger RNA labels
and/or mutations," he said. "Our computation result depends on these levels,
which may indicate a disease."
In their proof-of-concept experiments, the researchers mixed DNA
computers programmed to identify prostate cancer in a test tube with prostate
cancer cells. The computers were able to identify the cells and release
DNA strands designed to eradicate the cells. The researchers programmed
a second set of DNA computers to identify a certain form of lung cancer
cells, and the computers successfully identified those as well.
The method has the potential to detect multiple disease conditions
at once, said Benenson. This "makes the diagnosis very selective," he
The key to the method is that the tiny computer is made from a
material that is intrinsically compatible with living beings, said Benenson.
"In situ detection and analysis of molecular signals in living organisms
is impossible with electronic computers due to the insurmountable incompatibility
of the materials involved," he said.
The next step is to see if practical applications like real diagnosis
and cure are possible using the DNA computers, said Benenson. Even though
the materials are biologically compatible, the device itself "will require
major modifications to be made compatible with living systems," he said.
The first working smart drugs are likely to sense just a single
disease indicator and may become available within the next three to four
years. More elaborate smart drugs like the researchers' molecular-scale
computer could take 10 years to reach clinical trials, said Benenson.
Benenson's research colleagues were Binyamin Gil, Uri Ben-Dor,
Rivka Adar and Ehud Shapiro. The work appeared in the April 29, 2004 issue
of Nature. The research was funded by the Israeli Science Foundation,
the Moross Cancer Institute and the Minerva Foundation.
Timeline: 3-4 years, 10 years
Funding: Government; Private
TRN Categories: Biological, Chemical, DNA and Molecular
Story Type: News
Related Elements: Technical paper, "An Autonomous Molecular
Computer for Logical Control of Gene Expression," Nature, April 29, 2004
May 5/12, 2004
DNA bot targets cancer
Memory stores three
bits in one
Chaos seems to aid learning
Y switches set up
blocks prying eyes
Net lets hand-helds
view 3D data
could slow viruses
Nano test tubes fabricated
Research News Roundup
Research Watch blog
View from the High Ground Q&A
How It Works
News | Blog
Buy an ad link